Eckert & Ziegler : Presentation Pentixapharm Spring Conference Frankfurt

Eckert & Ziegler SE

Dr. Harald Hasselmann, CEO

Q1 results 2024

May 14, 2024

Disclaimer

This presentation contains forward-looking statements based on the beliefs of Eckert & Ziegler SE management. Such statements reflect current views of Eckert & Ziegler SE with respect to future events and results and are subject to risks and uncertainties. Actual results may vary materially from those projected here, due to factors including changes in general economic and business conditions, the introduction of competing products, lack of market acceptance of new products, services or technologies and changes in business strategy. Eckert & Ziegler SE does not intend or assume any obligation to update

these forward-looking statements.

The provision of presentations or recordings of webinars is exclusively for internal, business use. Presentations or recordings of webinars may only be passed on to third parties or reproduced with the prior written consent of Eckert & Ziegler SE. The independent production of recordings as well as their subsequent transfer to third parties also requires the prior written consent of Eckert & Ziegler SE.

All information contained in this presentation or webinar is provided without guarantee of accuracy,

completeness or currency. Any contractual obligation and/or liability in connection with the presentation or webinar, including vis-à-vis third parties, is excluded. Slides only for illustration, the spoken word shall be binding.

slides only for illustration - the spoken word shall be binding

2

Executive Board

Dr. Harald Hasselmann		Jutta Ludwig		Frank Yeager
Chairman of the Executive Board		Member of the Executive Board		Member of the Executive Board
Segment Medical		Asia Business		Segment Isotope Products

slides only for illustration - the spoken word shall be binding

3

The Nuclear Medicine Market - Development and its Pillars

Estimated Nuclear Medicine Market Size 2030: 30BN USD *

Financing Rounds & Investments 2023/24

	4.1BN USD
2.4BN USD			1.4BN USD
	1,0BN USD
152M USD	UP TO 425M USD		175M USD
142M USD	105M USD	47,7M EUR	90M USD

* MedRays Intell 2020

slides only for illustration - the spoken word shall be binding

4

Core Competences - Sustainably Targeting Market Developments

Gallium-68

"The Companion Diagnostic Isotope"

• Market Leader in Ga-68 generators
• Prerequisite for therapy patient selection

30BN

USD

Lutetium-177

"The Therapeutic Isotope of the Moment"

• EMA approval Q2/2024
• Broadly used (Pluvicto & Lutathera)
• Further drug products to be approved soon (2025)

Yttrium-90

"Pushing Medical Devices"

• Global core supplier for Y-90
• APAC Expansion ongoing

Actinium-225

"The Next Big Therapy Isotope"

• Pioneer: GMP grade Q1/2024
• Various trials ongoing with first commercial drug in 2028

Equipment & Services

"Facilitators & Enablers"

• Global radiopharmaceutical manufacturing
• Provision of infrastructure & equipment incl. hot cells

slides only for illustration - the spoken word shall be binding

5

Core Competences - Customers*

177Lu		225Ac		Contract
		Manufacturing

*For confidentiality reasons, only a selection of our customers can be mentioned. The list also shows those with reservation agreements only.

slides only for illustration - the spoken word shall be binding

6

Core Competences - Radioisotope Supply, Related Services and Equipment

Radio- pharmaceutical Development

Raw Material

Radioisotopes

Imaging

Sources

Radio- pharmaceutical Manufacturing

Industrial Measurement

Healthcare Professionals

Quality

Assurance

Patients

Scientific

Applications

Services and Equipment provided by Eckert & Ziegler

slides only for illustration - the spoken word shall be binding

7

Q1 2024 Operational Highlights

JAN 2024

JAN 2024

JAN 2024

FEB 2024

Manufacturing &	Actinium-225
Supply Partnership	Supply Agreement
with ARTBIO	with Full-Life
Collaboration to establish	Supply agreement to
manufacturing and	support clinical trials
delivery of ARTBIO's	development initiatives of
pipeline therapies using	Ac-225 labeled
their proprietary Pb-212	therapeutics
isolation technology

Supply of Nucleus

Radiopharma with

Ac-225 and Lu-177

Eckert & Ziegler serves as

core supplier for the

therapeutic radioisotopes used in Nucleus' CDMO services

Extension of

Gallium-68

Activities in Japan

Our proprietary

GalliaPharm® is stated as the single source of Ga-68 for a clinical trial of Novartis in Japan

slides only for illustration - the spoken word shall be binding

8

EZAG in a Nutshell

ISOTOPE PRODUCTS

Radiation

Sources

Services

Trade

Disposal

MEDICAL

Medical Devices

Pharmaceuticals

Lab Devices

Engineering

CMO / CDMO

9

slides only for illustration - the spoken word shall be binding

Segment Data (FY2023)

Isotope Products

• 584 employees (as of Dec. 2023)
• Revenue: 130,9 million EUR

▪	Rev. / Employee: ~ 224.000 EUR	Revenue	EBIT
▪	EBIT: 23,8 million EUR	53%	49%
Medical			47%	51%

• 374 employees (as of Dec. 2023)
• Revenue: 115,2 million EUR
• Rev. / Employee: ~ 308.000 EUR
• EBIT: 24,5 million EUR

slides only for illustration - the spoken word shall be binding

10